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Abstract
Background: Many in vitro studies have demonstrated that silencing of cancerous genes by siRNAs is a potential
therapeutic approach for blocking tumor growth. However, siRNAs are not cell type-selective, cannot specifically
target tumor cells, and therefore have limited in vivo application for siRNA-mediated gene therapy.
Results: In this study, we tested a functional RNA nanocomplex which exclusively targets and affects human
anaplastic large cell lymphoma (ALCL) by taking advantage of the abnormal expression of CD30, a unique surface
biomarker, and the anaplastic lymphoma kinase (ALK) gene in lymphoma cells. The nanocomplexes were
formulated by incorporating both ALK siRNA and a RNA-based CD30 aptamer probe onto nano-sized
polyethyleneimine-citrate carriers. To minimize potential cytotoxicity, the individual components of the
nanocomplexes were used at sub-cytotoxic concentrations. Dynamic light scattering showed that formed
nanocomplexes were ~140 nm in diameter and remained stable for more than 24 hours in culture medium. Cell
binding assays revealed that CD30 aptamer probes selectively targeted nanocomplexes to ALCL cells, and confocal
fluorescence microscopy confirmed intracellular delivery of the nanocomplex. Cell transfection analysis showed that
nanocomplexes silenced genes in an ALCL cell type-selective fashion. Moreover, exposure of ALCL cells to
nanocomplexes carrying both ALK siRNAs and CD30 RNA aptamers specifically silenced ALK gene expression,
leading to growth arrest and apoptosis.
Conclusions: Taken together, our findings indicate that this functional RNA nanocomplex is both tumor cell type-
selective and cancer gene-specific for ALCL cells.
Background
T h ed i s c o v e r yo fR N Ai n t e r f e r e n c e( R N A i ) ,t h ep r o c e s s
by which specific mRNAs are targeted for degradation
by complementary small interfering RNAs (siRNAs), has
enabled the development of methods for the silencing of
specific genes at the cellular level [1-3]. In vitro studies
demonstrated that siRNA-mediated silencing of onco-
genes induces growth arrest and death of tumor cells,
indicating their potential therapeutic value [4-7].
Although siRNAs are gene specific, they are not cell/tis-
sue-selective and therefore can not specifically target or
accumulate in tumor tissues. Therefore, an efficient cell/
tissue-specific delivery system is needed to make siRNA-
mediated gene therapy a feasible approach. In vivo deliv-
ery of functional RNAs can be achieved using either
viral carriers or non-viral cationic vectors. Although
viral carriers achieve high transfection efficiencies, con-
cerns about their safety, immunogenicity, and latent
pathogenic effects have convinced researchers to focus
on non-viral cationic carriers [8-11]. Among these catio-
nic carriers, polyethyleneimine (PEI) has been widely
studied due to its high cell transfection efficiency, strong
buffering capacity, and ability to release functional
nucleic acids from endosomes into the cytoplasm by
inducing osmotic endosomal rupture [12-19]. However,
PEI carriers alone are not cell/tissue-type specific, thus
reaching tumor sites in vivo requires high treatment
dosages of PEI, which may be toxic to normal tissues
[20,21]. This cytotoxicity of PEI has thus far prevented
its translation to the clinic [22]. While efforts to
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the required dosage of PEI could also reduce toxicity.
To gain cell specificity, the siRNA delivery system can
be combined with a target-specific ligand molecule
[23-26]. Although monoclonal antibodies have been
widely used as cell-targeting ligands, mouse monoclonal
antibodies are immunogenic in vivo and humanized
monoclonal antibodies are very costly and only available
for a limited number of ligands. Thus, scientists have
searched for other ligand molecules that are easier to
produce. Aptamers, short single-stranded oligonucleo-
tides (30-50 bases) represent one such class of new
small molecule ligands. In contrast to antibodies, apta-
mers are small oligonucleotides that exhibit no or mini-
mal antigenicity/immunogenicity, so they are more
suitable for in vivo u s ea sd i a g n o s t i co rt h e r a p e u t i c
agents [27-29]. Recently, a RNA aptamer was developed
that specifically binds to the CD30 protein in solution
[30]. In addition, we have shown that this RNA aptamer
selectively binds to intact CD30-expressing lymphoma
cells with binding characteristics similar to a CD30-spe-
cific antibody [31].
Anaplastic lymphoma kinase (ALK)-positive anaplastic
large cell lymphoma (ALCL) is an aggressive T-cell
lymphoma [32-34]. ALCL cells exhibit an abnormal
expression of the ALK oncogene and unique surface
expression of CD30 [35-37]. The presence of these
distinct molecular markers provides the rationale for
development of a lymphoma cell-selective and tumor
gene-specific therapeutic approach to treat ALCL.
Previous studies demonstrated that siRNA-mediated
knockdown of ALK gene expression promotes cell death
of ALCL cells [38-40]. Based on these findings, we
hypothesized that ALCL-selective delivery of a tumor
gene-specific siRNA could be developed by assembling a
functional RNA nanocomplex comprised of the CD30-
specfic aptamer and an ALK-targeted siRNA within
nano-sized PEI polymer carriers.
Results
Formulation of a nanocomplex containing both CD30
aptamer and ALK siRNA
Briefly, the nanocomplexes were assembled by incorpor-
ating the synthetic siRNA and CD30 aptamer into the
nano-sized carrier structure of PEI-citrate nanocores
(Figure 1A). The rationale for our nanocomplex design is
the CD30 aptamer provides selective binding of nano-
complexes to ALCL cells. The aptamer-mediated binding
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Figure 1 Development of a tumor cell type-selective and cancer gene-specific nanocomplex for ALCL cells. A, A nano-sized carrier core
structure was initially formed via aggregation of polyethyleneimine (PEI) and crosslinking with sodium citrate (PEI-citrate nanocore). The
synthetic RNA-based CD30 aptamers and ALK siRNA were then incorporated onto the PEI-citrate nanocore to form the nanocomplex. B, When
the functional RNA nanocomplex is added to cultures, the aptamer component will selectively target CD30-positive ALCL cells. Aptamer-
mediated cell binding will facilitate intracellular delivery of the nanocomplex. The siRNA component will subsequently silence the cellular ALK
gene, resulting in the growth arrest of ALCL cells.
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Page 2 of 12results in intracellular delivery of the ALK-targeted
siRNA component exclusively into ALCL cells and subse-
quent silencing of the cellular ALK gene (Figure 1B).
First, the nanocore structure was formed by electro-
static crosslinking of positively-charged PEI with nega-
tively-charged sodium citrate [41,42]. As shown in
Figure 2A, the size of the PEI-citrate nanocores
depended on the ratio (’R’) of citrate to PEI (charge/
charge) and the reaction time. For the present study a
‘R’ ratio of 1:1.5 with a reaction time of 5 minutes was
chosen to obtain an ~120-nm PEI-citrate nanocore
(Figure 2B). At the end of 5 minutes, the synthetic
CD30 aptamers and ALK siRNAs were incorporated
into the PEI-citrate nanocore carriers via non-covalent
bonds to form a nanocomplex with a peak hydrody-
namic diameter of ~140 nm (Figure 2B). However, the
distribution of nanocomplex size ranged from 60 to 260
nm with approximately 80% of nanocomplexes being
100 to 180 nm in diameter (Figure 2C). The size of
formed nanocomplexes was also confirmed by transmis-
sion electron microscopy (Additional File 1). Finally, the
size of nanocomplexes remained stable in cell culture
medium at room temperature for 24 hours (Figure 2D),
demonstrating colloidal stability of the nanocomplex.
Zeta potential measurements show that the positive
charge of PEI-citrate nanocore (+10 ± 0.6 mV) was
reversed after incorporation of the siRNA and aptamer
(-41 ± 0.9 mV). This was expected because of the
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Figure 2 Formulation of nanocomplex. A, Dynamic light scattering (DLS) measurement of PEI-citrate nanocores, which were formed using
different ‘R’ ratios of citrate to PEI (charge/charge). B, Assembly of the nanocomplexes by incorporation of PEI-citrate nanocores with synthetic
ALK siRNA and CD30 aptamers. The arrow indicates the addition of siRNA and aptamer components into the reaction mix. The size of the
nanocomplexes formed was measured over time by DLS. C, The frequency of the nanocomplexes with different sizes was calculated. D,
Nanocomplexes were incubated in cell culture medium, and the sizes were measured over time by DLS.
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Page 3 of 12negatively-charged nature of both the siRNA and apta-
mer that have complexed with the PEI-citrate nanocore.
Further, the potential of the nanocomplex dropped to
-25 ± 0.9 mV in the cell culture medium due to the
high ionic strength.
To evaluate whether nanocomplexes, or their compo-
nents, caused non-specific cytotoxicity, cultured Kar-
pas 299 cells were treated for 48 hours with the
individual nanocomplex components at their maximal
concentrations. After treatment, cell viability was evalu-
ated by flow cytometry. Treatment with 100 nM CD30
aptamer, 100 nM ALK siRNA, or 4.2 μMs o d i u mc i t r a t e
had no effect on cell viability (Figure 3A). Previous in
vitro studies showed that high concentrations of PEI
may be toxic to cells [20,21]. To determine a non-cyto-
toxic concentration of PEI, we treated Karpas 299 cells
with serial dilutions of PEI for 48 hours and monitored
cell viability by flow cytometry. As shown in Figure 3B,
5 μg/ml PEI was cytotoxic, significantly reducing cell
viability. However, the observed cytotoxicity decreased
as the PEI concentration decreased. Cytotoxicity was
undetectable with treatment of ≤1.10 μg/ml PEI (Figure
3C). Thus, to rule out any PEI-mediated non-specific
cellular effects, nanocomplexes made with a final PEI
concentration of 0.274 μg/ml were used for further
experiments. When used as a non-specific carrier for
cell gene delivery, a final PEI concentration of 5-10 μg/
m lw a sc o m m o n l yu s e d ,ad o s es h o w e dt ob eh i g h l y
cytotoxic [15-21].
CD30 aptamers mediate selective ALCL cell binding and
intracellular delivery of nanocomplexes
First, Cy5-conjugated ssDNA corresponding to the sense
sequence of the ALK siRNA was incorporated into nano-
cores at different ratios andu s e da sar e p o r t e rf o rP E I -
medicated non-specific cell binding. These reporter nano-
complexes were incubated with Karpas 299 cells for 30
minutes, and the resultant non-specific cell binding was
quantified by flow cytometry. As shown in Figure 4A, PEI-
mediated non-specific cell binding could be modulated by
altering the ratio of incorporated ssDNA and was comple-
tely eliminated when the ratio of PEI to ssDNA (moles of
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Figure 3 Cytotoxicity assays of individual nanocomplex components. A, Cultured Karpas 299 cells were treated for 48 hours with the
individual components of the nanocomplex at their maximal concentrations: 100 nM CD30 aptamer, 100 nM ALK siRNA, and 4.2 μM sodium
citrate, or vehicle only for the control group. Cell viability (%) was evaluated by flow cytometry using forward scatter (FSC) and side scatter (SSC)
parameters as indicated. B, Karpas 299 cells were treated with PEI at concentrations of 5.48 and 1.10 μg/ml for 48 hours, and viable cells were
quantified by flow cytometry, as above. C, Cell viability studies using serially diluted PEI ranging from 0.027 to 5.48 μg/ml.
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Page 4 of 12nitrogen in PEI to moles of phosphate in ssDNA) was ≤
1:1. Subsequently, to gain selective cell binding, the CD30
aptamer was incorporated into the PEI carrier along with
the Cy5-ssDNA to form new test nanocomplexes. Differ-
ent ratios of PEI carrier to total oligonucleotides were
tested as indicated, but the CD30 aptamer and Cy5-
ssDNA were used at a fixed ratio of 1:1 (mol/mol). As
shown in Figure 4B, the highest specific binding to Karpas
299 cells was observed when a 1:1 ratio of PEI carrier to
total amounts of aptamer and ssDNA (moles of nitrogen
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Figure 4 Optimization of the specific cell binding and carrying capacity of the nanocomplexes. A, Synthetic Cy5-conjugated ssDNA
reporter molecules were incorporated into the PEI-citrate nanocores at different ratios (moles of nitrogen in PEI to moles of phosphate in
ssDNA) as indicated. Reduction of the PEI-medicated non-specific cell binding was then monitored by flow cytometry. B, To gain specific cell
binding capacity, the CD30 aptamer was incorporated into PEI-citrate nanocores along with the Cy5-ssDNA reporter to form a test nanocomplex.
Different ratios of PEI-citrate nanocores to total oligonucleotides (moles of nitrogen in PEI/total moles of phosphate from both the aptamer and
ssDNA) were tested as indicated, while the aptamer and Cy5-ssDNA were used at a fixed ratio of 1:1 (mol/mol). The CD30 aptamer-mediated
specific binding to Karpas 299 cells was confirmed using flow cytometry. C, To optimize the maximal carrying capacity, the nanocomplex was
formulated using a fixed ratio of PEI-citrate nanocores to total oligonucleotides (1:1 ratio as showed in B), but the ratios of the CD30 aptamer
and Cy5-ssDNA reporter were altered as indicated (mol/mol). The carrying capacity of Cy5-ssDNA reporter by the nanocomplex with specific
binding to Karpas 299 cells was quantified using flow cytometry.
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Page 5 of 12in PEI to total moles of total phosphate from both the
aptamer and ssDNA) was used. Finally, to optimize the
carrying capacity, the nanocomplexes were formulated
using a fixed 1:1 ratio of PEI carrier to total oligonucleo-
tides as described above, but the ratios of the CD30 apta-
mer and Cy5-ssDNA (mol/mol) were altered. A maximal
carrying capacity of ssDNA by the nanocomplex was
demonstrated when the CD30 aptamer and ssDNA were
used at a ratio of 1:10 (Figure 4C).
For further confirmation, Karpas 299 cells and CD30-
negative Jurkat cells were treated with PEI carrier alone,
PEI carrier incorporated with the Cy5-ssDNA reporter
(but no CD30 aptamer), or nanocomplexes carrying
both the CD30 aptamer and the Cy5-ssDNA reporter.
The resultant cell binding was monitored by flow cyto-
metry (Figure 5). The presence of the CD30 aptamer,
nanocomplexes selectively bound Karpas 299 cells, but
not to Jurkat cells, which do not express the CD30
ligand (Figure 5A and 5B). In addition, aptamer-
mediated CD30 selective binding of the nanocomplexes
to Karpas 299 cells was also confirmed by fluorescent
microscopy. Finally, the biostability of the nanocom-
plexes was evaluated by pre-incubating the nanocom-
plexes in culture medium and then adding Karpas 299
or Jurkat cells at different time points as indicated in
Figure 5C. Specific cell binding of the nanocomplexes
was then quantified by flow cytometry. The nanocom-
plex was functionally stable in culture medium and
retained ~75% of its cell binding capacity after pre-
incubation for 8 hours, but after 12 hours the binding
capacity decreased to ~10% (Figure 5C).
To determine whether binding of the CD30 aptamer-
mediated to the cell surface induced nanocomplex
internalization, cells were incubated with the test nano-
complexes for 4 hours, the nuclei stained with DAPI,
and examined by confocal microscopy. As shown in Fig-
ure 5D, intracellular delivery of the nanocomplexes was
confirmed by observing the overlap of the Cy5-ssDNA
reporter (red) with the DAPI-stained cell nuclei (blue).
Control experiments using identically treated Jurkat
cells showed no cellular binding or intracellular delivery
of the nanocomplex.
Nanocomplexes introduce functional siRNAs
into ALCL cell
First, to determine whether siRNAs remain functional
after incorporation into the nanocomplexes, we first
tested a nanocomplex containing enhanced green fluor-
escent protein (eGFP)-targeted siRNAs. For quantitative
measurement of gene silencing, Karpas 299 and Jurkat
reporter cells that stably express eGFP and luci-
ferase gene were utilized [43]. The cells were treated
with nanocomplexes containing the CD30 aptamer
and eGFP siRNA for 2 days, and changes in eGFP
expression were quantified by flow cytometry. As
s h o w ni nF i g u r e6 A ,a7 1 %r e d u c t i o ni ne G F Pe x p r e s -
sion was detected in Karpas 299 cells treated with
nanocomplexes containing eGFP-targeted siRNA, but
there was no reduction in cells treated with nanocom-
plexes containing an irrelevant control siRNA. Further,
siRNA delivery was CD30 specific, because no change
in eGFP expression was observed in CD30 negative Jur-
kat cells after eGFP siRNA-containing nanocomplex
treatment. We also demonstrated that gene silencing
was not limited to eGFP by making nanocomplexes
c o n t a i n i n gs i R N As p e c i f i cf o rt h el u c i f e r a s eg e n ea n d
CD30 aptamer for ALCL targeting. Cells were treated
with the luciferase-specific siRNA nanocomplexes and 2
days post-treatment, luciferin was added to the cell cul-
tures and luciferase activity detected by biolumines-
cence scanning. Treatment with the nanocomplex
selectively silenced the luciferase gene in Karpas 299
cells (a 76% reduction in cellular luciferase activity), but
not in CD30-negative Jurkat cells (Figure 6B). To rule
out non-specific cytotoxicity of the nanocomplexes, cell
viability was simultaneously monitored. As before,
exposure of Karpas 299 cells and Jurkat cells to the
nanocomplexes had no effect on cell viability (Figure
6C). Moreover, cells were treated with the nanocom-
plexes for luciferase gene silencing as described above
and also in the presence of fetal calf serum. Gene
silencing studies showed that the presence of 10%
serum had no effect on the nanocomplex-induced lym-
phoma cell type-dependent gene silencing (Figure 6D),
further confirming the biostability of the formulated
nanocomplexes.
Nanocomplex treatment silences ALK expression and
causes growth arrest of ALCL cells
To determine if nanocomplex-mediated delivery of an
ALK-targeted siRNA could knockdown gene expression,
we assembled nanocomplexes by incorporating both
CD30 aptamer and ALK siRNA into the PEI-citrate carrier
(Figure 1A). Cultured Karpas 299 cells were treated with
the nanocomplex for 2 days and ALK gene silencing was
monitored by immunoblotting with an anti-ALK protein
antibody. Treating cells with nanocomplexes containing
ALK siRNA resulted in specific knockdown of the nucelo-
phosmin-ALK (NPM-ALK) fusion protein expression but
did not affect cellular b-actin expression, used as an inter-
nal control (Figure 7A). Additionally, immunocytochem-
ical staining of nanocomplex-treated Karpas 299 cells was
performed to assess NPM-ALK fusion protein expression
(Figure 7B). As with the immunoblotting analysis, a
marked decrease in NPM-ALK protein expression was
observed in cells treated with the ALK-siRNA nanocom-
plexes but not with nanocomplexes containing am irrele-
vant control siRNA.
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Page 6 of 12Figure 5 CD30 aptamer-mediated selective cell binding and intracellular delivery of nanocomplexes. A, Cultured Karpas 299 cells were
treated with nanocomplexes containing the CD30 aptamer and Cy5-ssDNA reporter. Specific cell binding was detected by flow cytometry
(top row), as well as fluorescence microscopy (bottom row) paired with light microscopy (middle row). To rule out non-specific cell binding,
PEI-citrate nanocores alone or PEI-citrate nanocores containing the Cy5-ssDNA reporter (but no CD30 aptamer component) were used in control
cultures. B, Cultured CD30-negative Jurkat cells were tested under the same treatment conditions. C, To assess functional biostability, the
nanocomplex was pre-incubated in culture medium for up to 24 hours and changes in its cell binding capacity was kinetically monitored (%).
CD30-negative Jurkat cells were used as a background binding control. D, To detect intracellular delivery, Karpas 299 cells (top row) and control
Jurkat cells (bottom row) were treated with the nanocomplex containing both Cy5-ssDNA reporter and CD30 aptamer for 4 hours followed by
quick nuclear staining with DAPI. As indicated, the treated cells were examined using light and confocal microscopy to visualize the
DAPI-stained nuclei (blue) and the Cy5 reporter signal of the nanocomplex (red). Merged images of the DAPI-stained nuclei and Cy5 reporter
signal indicate the intracellular localization of the nanocomplex.
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Page 7 of 12Figure 6 Lymphoma cell type-dependent gene silencing by the nanocomplexes. A, Stably-expressing eGFP and luciferase Karpas 299 and
Jurkat cells were used as reporters for the gene silencing studies. The cells were treated with the nanocomplexes containing eGFP siRNA along
with the CD30 aptamer, non-relevant control siRNA along with CD30 aptamer, or left untreated for 2 days. Reduction of eGFP expression (%)
was quantified by flow cytometry. B, Similarly, the cells were treated with nanocomplexes containing luciferase siRNA along with the CD30
aptamer for 2 days. After addition of luciferin into the cultures, the cellular luciferase activity was detected by bioluminescence scanning. C,T o
rule out non-specific cytotoxicity, relative viabilities (%) in the same sets of cells described in B were simultaneously examined by counting viable
cell numbers. D, Cells were treated with the nanocomplexes as described in B and also in the presence of 5% or 10% fetal calf serum. After
culture for 2 days at 37°C, cellular luciferase activity was detected by bioluminescence scanning.
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Page 8 of 12To examine changes in Karpas 299 cell viability, cells
were treated with ALK-siRNA nanocomplexes, as
described above, and growth kinetics and cell viability
were simultaneously measured at 2 and 4 days post-
treatment. Cells were treated for 4 days because the cel-
lular NPM-ALK fusion protein has a long half life time,
≥48 hours. As shown in Figure 7C, treating Karpas
299 cells with the nanocomplex significantly inhibited
cell growth (P < 0.05). In contrast, the growth kinetics
of nanocomplex-treated Jurkat cells was unaffected.
To assess apoptosis, Karpas 299 cells were treated with
the nanocomplex for 24 hours, as described above,
stained with FITC-conjugated Annexin V, and analyzed
by flow cytometry. Nanocomplex-treatment significantly
increased the percentage of apoptotic cells from a basal
level of 2.2% to 14.1% (Figure 7D, P < 0.05).
Discussion
An ideal in vivo siRNA carrier system will safely trans-
port the ‘cargo’ to the desired destination, release a
functional cargo in a tissue/cell specific manner, and
have no off-target or adverse drug effects. In this study,
we have developed this type of carrier system by formu-
lating a functional RNA nanocomplex that is both
tumor cell type-selective and cancer gene-specific for
ALCL. Advantages of these nanocomplexes include:
1) incorporating siRNAs into a nano-sized carrier will
increase their physical size and could prevent the rapid
elimination of siRNA from the blood circulation in vivo;
2) incorporating CD30 aptamers will enable specific
accumulation of the nanocomplexes within tumor sites
and eliminate potential off target side effects of the
nanocomplex components; and 3) it is possible to
Nanocomplex with 
control siRNA
Days after treatment with nanocomplex
Nanocomplex with 
ALK siRNA
B
Jurkat cells C
V
i
a
b
l
e
 
c
e
l
l
s
 
(
1
0
4
/
m
l
)
Karpas 299 cells
A
p
o
p
t
o
t
i
c
 
r
a
t
e
(
%
)
A
D
(-): No treatment
C: Nanocomplex with control siRNA
ALK: Nanocomplex with ALK siRNA
(-)      C    ALK
(-)                C             ALK
Cell treatment
Karpas 299 cells
2
4
6
8
12
10
024
2
4
6
8
10 **
0 24
**
0
5
10
15 **
NPM-ALK fusion protein
E-actin protein
No treatment
Nanocomplex with control siRNA
Nanocomplex with ALK siRNA
(-): No treatment
C: Nanocomplex with control siRNA
ALK: Nanocomplex with ALK siRNA
Figure 7 ALK gene-silencing and growth inhibition of ALCL cells by functional RNA nanocomplexes. A, Cultured Karpas 299 cells were
treated with the nanocomplex containing both ALK siRNA and CD30 aptamer for 4 days. Cellular proteins were then separated by
electrophoresis and ALK fusion proteins (NPM-ALK) were detected by immunoblotting. Cellular b-actin protein expression was also measured as
an internal control for gene expression. B, Cellular ALK fusion protein expression in the same set of treated Karpas 299 cells was also
simultaneously detected by immunocytochemical staining. C, To study the corresponding effects on cellular proliferation and viability when the
ALK gene was silenced, Karpas 299 and control Jurkat cells were treated with the nanocomplexes containing ALK siRNA or irrelevant control
siRNA, or were not treated. The number of viable cells was counted under each treatment condition on days 2 and 4 post-treatment. D,T o
assess apoptosis, Karpas 299 cells were treated as described above for 2 days and then stained with FITC-conjugated Annexin V. The number of
apoptotic cells (%) was measured by flow cytometry.
**P < 0.05.
Zhao et al. Journal of Nanobiotechnology 2011, 9:2
http://www.jnanobiotechnology.com/content/9/1/2
Page 9 of 12incorporate more than one siRNA and/or therapeutic
drug into the nanocomplex to generate additive or
synergistic repressive effects on tumor cells. The use of
specific ligands for cell targeting and reduction of the
PEI dose is critical for in vivo feasibility. PEI polymers
have been used for cell transfection at concentrations
ranging from 5 to 10 μg/ml [15-19], at which moderate
cytotoxicity has been reported [20,21]. As demonstrated
in this study, incorporating the CD30 aptamer allowed
us to use a sub-toxic dose of the PEI carrier in the
nanocomplex, less than 1/20 of the reported cytotoxic
concentration. It is notable that under in vivo condi-
tions, the CD30 aptamer-mediated cell binding will
likely result in an accumulation of the nanocomplexes
exclusively in lymphoma tumor tissues and increase the
local PEI concentration, possibly reaching a toxic dose.
Interestingly, the increased PEI concentration within
tumor tissues may enhance the in vivo therapeutic effect
of the nanocomplex, but have no adverse effect on nor-
mal tissues.
Conclusions
In this study, we have described an approach for devel-
oping therapeutic agent by formulating a nanocomplex
that is both tumor cell-selective and cancer gene-specific
for ALCL. The nanocomplexes are specific and non-
cytotoxic to lymphoma cells, which advance great
potential for their clinical applications.
Methods
Chemical reagents and oligonucleotide synthesis
Branched polyethyleneimine (60 kDa) was purchased
from Sigma-Aldrich (Catalog #P3143, St. Louis, MO).
Sodium citrate was obtained from Fisher Scientific
(Pittsburgh, PA). For silencing the enhanced green fluor-
escent protein gene (eGFP), eGFP-targeted siRNA was
p u r c h a s e da l o n gw i t hap a i r e dc o n t r o ls i R N Af r o m
Ambion (catalog # AM4626, Foster City, CA). The
ALK-targeted siRNA was synthesized by Ambion using
the reported sequences: sense, 5’-CACUUAGUAGU-
GUACCGCCtt-3’ and antisense, 5’-GGCGGUACACUA-
CUAAGUGtt-3’ [38]. A reporter for the cell binding
assays was constructed by synthesizing a single-stranded
DNA (ssDNA) oligonucleotide containing the sense
ALK siRNA sequence conjugated at the 5’ end to the
fluorochrome Cy5 (excitation 645 nm/emission 665).
The CD30 aptamer was synthesized by Bio-Synthesis
(Lewisville, TX), as previously described [31] using the
following sequence: 5’-GAUUCGUAUGGGUGGGAU
CGG GAAGGGCUACGAACACCG-3’.
Formulation and characterization of the nanocomplex
To generate the PEI polymer carrier, we used sodium
citrate to crosslink PEI molecules. The PEI-citrate core
structure (nanocore) was formed by mixing one part by
volume of a 100 μg/ml pH 6.0 PEI solution with six parts
by volume of sodium citrate. To obtain PEI-citrate nano-
cores of the optimal size, different ‘R’ ratios (defined as
the ratio of the number of carboxylate groups from
citrate to the number of primary amine groups from PEI)
were tested. These ratios ranged from 10 to 1 and were
obtained by changing the concentration of the citrate
solution. The size of the PEI-citrate nanocores produced
for each R ratio was determined by obtaining dynamic
light scattering measurement (DLS) using a Brookhaven
ZetaPALS with a BI-9000AT digital autocorrelator at a
wavelength of 656 nm. Diameters were obtained by fit-
ting DLS correlation with the CONTIN routine available
through the instrument software 9KDLSW. Electro-
phoretic mobility was also determined with ZetaPALS
using a dip-in (Uzgiris type) electrode in 4-mL polystyr-
ene cuvettes, and the zeta potential was calculated using
the Smoluchowski model. To assemble the nanocomplex,
three parts by volume of synthetic CD30 aptamers
(10nM) and siRNAs (100nM) (or Cy5-labeled ssDNA for
validation purposes) were added to the nanocore reaction
5 minutes after initiation and were incorporated into the
PEI-citrate nanocores through non-covalent charge
forces (Figure 1A). To confirm the colloidal stability of
the assembled nanocomplexes, they were incubated in
RPMI 1640 cell culture medium at room temperature
and the nanocomplex size was monitored by DLS over
time.
Cell binding assays
Karpas 299 cells (a human CD30-expressing ALCL cell
line from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig) and Jurkat
cells (a CD30-negative human leukemia/lymphoma cell
line from ATCC, Manassas, VA) were used in this
study. Cells (2 × 10
5) were incubated with PEI-citrate,
PEI-citrate/ssDNA(Cy5), or PEI-citrate/ssDNA(Cy5)/
Aptamer, as indicated in Figure 5, in 0.5 ml of culture
medium for 30 minutes at room temperature. Cell bind-
ing of the nanocomplexes was analyzed by flow cytome-
try (LSRII, BD Biosciences) and fluorescent microscopy
(Olympus IX71 inverted microscope) to detect cell sur-
face Cy5 signal. To test their biostability, nanocomplexes
were incubated in RPMI 1640 medium, and CD30 apta-
mer-mediated cell binding was examined at the indi-
cated intervals over 24 hours.
In vitro functional assays
Cytotoxicity assay: the individual components were
added into Karpas 299 cell cultures (2 × 10
5/sample) at
their maximal concentrations: 100nM CD30 aptamer,
100 nM ALK gene-targeting siRNA, and 4.2 μM sodium
citrate (pH 6.0). After 48 hours, cells were harvested,
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forward and side scatter parameters. PEI toxicity was
also examined by adding serial dilution ranging from
5.48 μg/ml to 0.027 μg/ml to the cell cultures and evalu-
ated as described above. Cell viability assay: cells (2 ×
10
5/sample) were treated as indicated and stained with
0.1% trypan blue in PBS for 15 minutes. Viable cells
were counted using a hemocytometer and light micro-
scope. The relative rate of cell growth was determined
by calculating the ratio of the number of viable cells in
treated samples to the number of cells in the control
samples (no treatment). Cell apoptosis assay: cells (2 ×
10
5/sample) were treated for 24 hours as indicated and
stained with FITC-conjugated Annexin V using a kit
from BD Biosciences. Apoptotic cells were detected by
flow cytometry.
Confocal fluorescence microscopy
To demonstrate cell-selective intracellular delivery of the
nanocomplex, cultured cells (2 × 10
5/sample) were treated
with the nanocomplex diluted in 0.5 ml of RPMI
1640 medium without serum for 4 hours at 37°C. Cells
were then washed twice with PBS and stained with 1 μg/
ml 4’-6-diamidino-2-phenylindole (DAPI, Invitrogen) for
15 minutes to label nuclei. Lastly, cells were cytospined
onto slide and examined using a laser scanning confocal
microscope (Olympus, Fluo ViewTM 1000) at 400 ×
magnification.
Gene silencing studies
To validate ALCL-selective gene silencing, an eGFP-spe-
cific nanocomplex was generated as indicated in Figure
1B and incubated with 2 × 10
5 eGFP-expressing Karpas
299 or Jurkat cells (40) at PEI concentration of 0.274
μg/ml in 0.5 ml of RPMI 1640 medium for 4 hours at
37°C with or without fetal calf serum as indicated in the
figures. The cells were then washed twice with PBS and
cultured in medium containing 10% FBS. Expression of
eGFP was evaluated by flow cytometry on day 2 post-
treatment. Nanocomplexes containing luciferase-targeted
siRNAs (Ambion, Austin, TX) were also tested in the
luciferase-transfected Karpas 299 or Jurkat cells (40).
Changes in luciferase activity in the cultures were evalu-
ated by bioluminescence scanning.
To silence ALK expression, cultured Karpas 299 cells
were treated with nanocomplexes containing ALK-tar-
geted siRNAs at a PEI concentration of 0.274 μg/ml, as
described above. eGFP-specific nanocomplexes were uti-
lized as an irrelevant gene silencing control. For immu-
nocytochemical studies, cells were harvested at day 2
post-treatment, and cytospins were prepared with a cell
preparation kit (BD Biosciences). The cellular nucelo-
phosmin-ALK fusion protein was detected using a
mouse anti-human ALK antibody (1:300 dilution, BD
Biosciences) and visualized with the DAKO ChemMate
detection kit using a horseradish peroxidase-conjugated
rabbit anti-mouse antibody and the color development
substrate DAB. Images were taken using a light micro-
scope. In addition, ALK fusion protein expression in the
treated cells was examined by immunoblotting, as pre-
viously described [43].
Statistical analysis
All experiments were performed greater than or equal
t ot h r e et i m e s .D a t aw e r ea n a l y z e db yS t u d e n t ’s t test.
P values of less than 0.05 were considered significant.
Additional material
Additional file 1: Electron microscopy of the nanocomplexes.
Approximately 2 μl of the nanocomplex solution composed of PEI-citrate
nanocores, ALK siRNA, and the CD30 aptamer were dried on an ultrathin
carbon film on a carbon support with holes and imaged with a JEOL
1230 high contrast transmission electron microscope operating at an
accelerating voltage of 120 V. The arrow points to a nanocomplex. 200
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